These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

82 related articles for article (PubMed ID: 8468727)

  • 1. Reduction in vasomotor symptoms from tamoxifen over time.
    Love RR; Feyzi JM
    J Natl Cancer Inst; 1993 Apr; 85(8):673-4. PubMed ID: 8468727
    [No Abstract]   [Full Text] [Related]  

  • 2. Safety of tibolone in the treatment of vasomotor symptoms in breast cancer patients--design and baseline data 'LIBERATE' trial.
    Kenemans P; Kubista E; Foidart JM; Yip CH; von Schoultz B; Sismondi P; Vassilopoulou-Sellin R; Beckmann MW; Bundred NJ; Egberts J; van Os S; Planellas J
    Breast; 2007 Dec; 16 Suppl 2():S182-9. PubMed ID: 17983942
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Symptoms and QOL as Predictors of Chemoprevention Adherence in NRG Oncology/NSABP Trial P-1.
    Land SR; Walcott FL; Liu Q; Wickerham DL; Costantino JP; Ganz PA
    J Natl Cancer Inst; 2016 Apr; 108(4):. PubMed ID: 26615179
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Reply to K.I. Pritchard.
    Fontein DB; van de Velde CJ;
    J Clin Oncol; 2013 Dec; 31(35):4477-9. PubMed ID: 24190123
    [No Abstract]   [Full Text] [Related]  

  • 5. Treatment-emergent endocrine symptoms and the risk of breast cancer recurrence: a retrospective analysis of the ATAC trial.
    Cuzick J; Sestak I; Cella D; Fallowfield L;
    Lancet Oncol; 2008 Dec; 9(12):1143-8. PubMed ID: 18976959
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Prospective study on gynaecological effects of two antioestrogens tamoxifen and toremifene in postmenopausal women.
    Marttunen MB; Cacciatore B; Hietanen P; Pyrhönen S; Tiitinen A; Wahlström T; Ylikorkala O
    Br J Cancer; 2001 Apr; 84(7):897-902. PubMed ID: 11286468
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Specific adverse events predict survival benefit in patients treated with tamoxifen or aromatase inhibitors: an international tamoxifen exemestane adjuvant multinational trial analysis.
    Fontein DB; Seynaeve C; Hadji P; Hille ET; van de Water W; Putter H; Kranenbarg EM; Hasenburg A; Paridaens RJ; Vannetzel JM; Markopoulos C; Hozumi Y; Bartlett JM; Jones SE; Rea DW; Nortier JW; van de Velde CJ
    J Clin Oncol; 2013 Jun; 31(18):2257-64. PubMed ID: 23610112
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Clinical Pearls in women's health.
    Faubion SS; Litin SC; Bundrick JB
    Dis Mon; 2017 Jun; 63(6):149-157. PubMed ID: 28651691
    [No Abstract]   [Full Text] [Related]  

  • 9. Double-blind, placebo-controlled, crossover trial of propranolol as treatment for menopausal vasomotor symptoms.
    Alcoff JM; Campbell D; Tribble D; Oldfield B; Cruess D
    Clin Ther; 1981; 3(5):356-64. PubMed ID: 7471131
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Influence of hormone replacement therapy on tamoxifen-induced vasomotor symptoms.
    Sestak I; Kealy R; Edwards R; Forbes J; Cuzick J
    J Clin Oncol; 2006 Aug; 24(24):3991-6. PubMed ID: 16921052
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Acupuncture in the control of vasomotor symptoms caused by tamoxifen.
    Towlerton G; Filshie J; O'Brien M; Duncan A
    Palliat Med; 1999 Sep; 13(5):445. PubMed ID: 10659122
    [No Abstract]   [Full Text] [Related]  

  • 12. A 12-week clinical trial determining the efficacy of synthetic conjugated estrogens, A (SCE), in the treatment of vasomotor symptoms in menopausal women.
    Stevens RE; Hanford K; Wason S; Cusack SL; Phelps KV
    Int J Fertil Womens Med; 2000; 45(4):264-72. PubMed ID: 10997482
    [TBL] [Abstract][Full Text] [Related]  

  • 13. [The effect of transdermal hormone replacement therapy on vasomotor symptoms in perimenopausal women].
    Rozmus-Warcholińska W; Skrzypulec V; Drosdzol A; Kowalczyk R; Nowosielski K; Piela B; Walaszek A
    Wiad Lek; 2004; 57 Suppl 1():254-8. PubMed ID: 15884251
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Symptoms associated with tamoxifen treatment in postmenopausal women.
    Love RR; Cameron L; Connell BL; Leventhal H
    Arch Intern Med; 1991 Sep; 151(9):1842-7. PubMed ID: 1888251
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Another multibotanical for vasomotor symptoms: some lessons learned.
    Newton KM
    Menopause; 2010 Mar; 17(2):237-8. PubMed ID: 20142786
    [No Abstract]   [Full Text] [Related]  

  • 16. Ospemifene's effect on vasomotor symptoms: a post hoc analysis of phase 2 and 3 clinical data.
    Constantine GD; Archer DF; Pollycove R; Jiang W; Altomare C; Pinkerton JV
    Menopause; 2016 Sep; 23(9):957-64. PubMed ID: 27404027
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Treatment-associated musculoskeletal and vasomotor symptoms and relapse-free survival in the NCIC CTG MA.27 adjuvant breast cancer aromatase inhibitor trial.
    Stearns V; Chapman JA; Ma CX; Ellis MJ; Ingle JN; Pritchard KI; Budd GT; Rabaglio M; Sledge GW; Le Maitre A; Kundapur J; Liedke PE; Shepherd LE; Goss PE
    J Clin Oncol; 2015 Jan; 33(3):265-71. PubMed ID: 25512454
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Quality of life in the intergroup exemestane study: a randomized trial of exemestane versus continued tamoxifen after 2 to 3 years of tamoxifen in postmenopausal women with primary breast cancer.
    Fallowfield LJ; Bliss JM; Porter LS; Price MH; Snowdon CF; Jones SE; Coombes RC; Hall E
    J Clin Oncol; 2006 Feb; 24(6):910-7. PubMed ID: 16484701
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Physical activity alone and in combination with hormone replacement therapy on vasomotor symptoms in postmenopausal women.
    Li S; Holm K
    West J Nurs Res; 2003 Apr; 25(3):274-88; discussion 289-93. PubMed ID: 12705112
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Patient-reported symptoms and quality of life during treatment with tamoxifen or raloxifene for breast cancer prevention: the NSABP Study of Tamoxifen and Raloxifene (STAR) P-2 trial.
    Land SR; Wickerham DL; Costantino JP; Ritter MW; Vogel VG; Lee M; Pajon ER; Wade JL; Dakhil S; Lockhart JB; Wolmark N; Ganz PA
    JAMA; 2006 Jun; 295(23):2742-51. PubMed ID: 16754728
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 5.